The company's product is therapeutically equivalent to AstraZeneca Pharmaceuticals' Atacand tablets which are indicated for treatment of hypertension, Alembic today said in a regulatory filing.
As per IMS data, candesartan cilexetil tablets had an estimated market size of USD 27 million in the US market for twelve months ended December 2016.
Alembic now has a total of 57 abbreviated new drug application (ANDA) approvals from the USFDA.
Shares of the company today closed 2.28 per cent higher at Rs 534.90 on BSE.
Disclaimer: No Business Standard Journalist was involved in creation of this content